<DOC>
	<DOC>NCT00047775</DOC>
	<brief_summary>A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.</brief_summary>
	<brief_title>African-American Heart Failure Trial</brief_title>
	<detailed_description>The overall objective is confirmation of BiDilâ€™s Safety and Efficacy in African-American (AFA) Patients with Moderate to Severe Symptomatic Heart Failure.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>African American male or female 18 years or older. NYHA Class 3 &amp; 4. Have either a resting LVEF less than or equal to 35% (by any method) or a resting LVIDD greater than 2.9 cm/m2 BSA (or greater than 6.5 cm) with LVEF less than 45% (by echocardiogram).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
</DOC>